Recruiting
Diffuse large B-cell lymphoma refractory+1
RecruitingRegistered drugNo placebo
Glofitamab plus drug combination for relapsed/refractory large B‑cell lymphoma in high‑risk second‑line patients eligible for CAR‑T therapy
Registered drugNo placebo
- Disease:Diffuse large B-cell lymphoma refractoryDiffuse large B-cell lymphoma recurrent
- Substances:GlofitamabObinutuzumab+2
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Glofitamab
- Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH





